--David Kappos (currently head of USPTO) on patents
ONE way to describe patents in the context of software is that they are a soft extension of copyrights, where mere ideas -- not implementations -- are being blocked by a monopoly holder on particular ideas. When it comes to APIs, this type of monopoly cannot even be worked around.
Robert McClelland alerts us to the unfortunate news that our elected officials have caved in to what the big pharma companies wanted and agreed to a new plan that would give a twelve-year monopoly on these sorts of "biosimilars." It's still not clear why this is needed at all, other than to wipe out competition and make drugs much more expensive. The two congressional reps who pushed this through were Representatives Anna Eshoo and Joe Barton. This is no surprise from Barton, but Eshoo, who represents part of Silicon Valley should know better than to be increasing monopoly protections.
Facebook was ordered by a judge in the District of Delaware’s District Court this week to release its entire source code to Leader Technologies Inc., a web-based collaboration platform developer. Leader, based in Columbus, Ohio, filed a patent infringement lawsuit against Facebook in November 2008. According to Law360, Leader alleges that the social network has “deliberately infringed a patent related to the management and storage of electronic information.”
Comments
aeshna23
2009-08-06 16:09:22
Jose_X
2009-08-06 16:24:02
The research costs are unavoidable only to the extent they require expensive machinery/materials/etc. As far as computer processing and human power, there are many ready to lend a hand there (with nonprofit and profit motives).
Manufacturing drugs certainly has costs compared to say manufacturing/distributing software. However, the mark up is also very high for the pills.